Details

Autor(en) / Beteiligte

• Li, Yan
• Zhou, Yun-Feng
• Liang, Han
• Wang, Hua-Qing
• Hao, Ji-Hui
• Zhu, Zheng-Gang
• Wan, De-Seng
• Qin, Lun-Xiu
• Cui, Shu-Zhong
• Ji, Jia-Fu
• Xu, Hui-Mian
• Wei, Shao-Zhong
• Xu, Hong-Bin
• Suo, Tao
• Yang, Shu-Jun
• Xie, Cong-Hua
• Yang, Xiao-Jun
• Yang, Guo-Liang

Titel

Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies

Ist Teil von

• World journal of gastroenterology : WJG, 2016-08, Vol.22 (30), p.6906-6916

Ort / Verlag

United States: Baishideng Publishing Group Inc

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Locoregional spread of abdominopelvic malignant tumors frequently results in peritoneal carcinomatosis(PC). The prognosis of PC patients treated by conventional systemic chemotherapy is poor, with a median survival of < 6 mo. However, over the past three decades, an integrated treatment strategy of cytoreductive surgery(CRS) + hyperthermic intraperitoneal chemotherapy(HIPEC) has been developed by the pioneering oncologists, with proved efficacy and safety in selected patients. Supported by several lines of clinical evidence from phases Ⅰ, Ⅱ and Ⅲ clinical trials, CRS + HIPEC has been regarded as the standard treatment for selected patients with PC in many established cancer centers worldwide. In China, an expert consensus on CRS + HIPEC has been reached by the leading surgical and medical oncologists, under the framework of the China Anti-Cancer Association. This expert consensus has summarized the progress in PC clinical studies and systematically evaluated the CRS + HIPEC procedures in China as well as across the world, so as to lay the foundation for formulating PC treatment guidelines specific to the national conditions of China.